Biotech Buzz: VIRX Cuts 23% Jobs, FDA Oks New Drug For Hypoparathyroidism, SIGA Down But Not Out

This week, once again, companies across the biotech sector continued to re-evaluate their pipelines and trim their workforces in a bid to conserve cash and extend their financial runway. Meanwhile, the regulatory landscape saw positive momentum with both new drug approvals and expanded indications.

from RTT - Top Story https://ift.tt/L509vZN
via IFTTT